Telix Pharmaceuticals (NASDAQ:TLX) Shares Up 9.2% - Time to Buy?

Key Points

• Telix Pharmaceuticals shares surged by 9.2%, closing at $10.98 after trading as high as $11.00 amid an increase in trading volume.
• Analysts have generally rated the stock as a "Moderate Buy," with a consensus price target of $21.00 following recent rating updates from firms like Citigroup and HC Wainwright.
• Institutional investment in Telix Pharmaceuticals has increased, with several funds acquiring new positions totaling nearly $1.5 million in recent quarters.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s stock price was up 9.2% during trading on Tuesday . The company traded as high as $11.00 and last traded at $10.98. Approximately 141,538 shares traded hands during trading, an increase of 103% from the average daily volume of 69,696 shares. The stock had previously closed at $10.05.

Analyst Ratings Changes

Several equities analysts recently issued reports on TLX shares. Citigroup began coverage on Telix Pharmaceuticals in a research note on Thursday, September 18th. They set a "buy" rating and a $22.00 target price on the stock. HC Wainwright cut their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, September 10th. UBS Group reduced their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Tuesday. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th. Finally, Wedbush restated an "outperform" rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $21.00.

Telix Pharmaceuticals Stock Up 8.3%

The stock's 50 day moving average price is $11.77 and its 200-day moving average price is $15.04. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78.

Institutional Trading of Telix Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Private Advisor Group LLC acquired a new position in shares of Telix Pharmaceuticals in the 1st quarter worth approximately $170,000. IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth $213,000. Blair William & Co. IL acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at about $217,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Telix Pharmaceuticals in the second quarter worth $297,000. Finally, ABC Arbitrage SA acquired a new position in Telix Pharmaceuticals in the 1st quarter valued at approximately $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.